 Iressa epidermal growth factor tyrosine kinase inhibitor EGFR-TKI has been reported to activity against Non-small-cell Lung Cancer NSCLC failed previous chemotherapy. UFUR was found to have anti-angiogenesis effect when long term treatment was given. Combination of EGFR-TKI and anti-angiogenesis agents is a novel treatment. 